829 related articles for article (PubMed ID: 32536199)
21. [Renal effects of sodium-glucose cotransporter 2 inhibitors in patients with cardiovascular disease with and without chronic kidney disease].
Benvenuto M; Panzarella G; Shehaj E; Valenti C; Caldarola P; Colivicchi F; Gabrielli D; Iacoviello M;
G Ital Cardiol (Rome); 2023 Mar; 24(3):188-195. PubMed ID: 36853155
[TBL] [Abstract][Full Text] [Related]
22. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.
Bailey CJ; Day C; Bellary S
Curr Diab Rep; 2022 Jan; 22(1):39-52. PubMed ID: 35113333
[TBL] [Abstract][Full Text] [Related]
23. Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?
Neuen BL; Jardine MJ; Perkovic V
Nephrol Dial Transplant; 2020 Jan; 35(Suppl 1):i48-i55. PubMed ID: 32003833
[TBL] [Abstract][Full Text] [Related]
24. The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys.
Lioudaki E; Joslin JR; Trachanatzi E; Androulakis E
Rev Cardiovasc Med; 2022 Mar; 23(3):82. PubMed ID: 35345249
[TBL] [Abstract][Full Text] [Related]
25. Can chronic kidney disease lead to chronic heart failure, and does worsening chronic heart failure lead to chronic kidney disease progression.
Leon SJ; Tangri N
Curr Opin Nephrol Hypertens; 2022 Mar; 31(2):205-211. PubMed ID: 34954720
[TBL] [Abstract][Full Text] [Related]
26. Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease.
Mima A
Adv Ther; 2021 May; 38(5):2201-2212. PubMed ID: 33860925
[TBL] [Abstract][Full Text] [Related]
27. Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure.
Seferović PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Çavuşoğlu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferović J; Jhund PS; Dattilo G; Čelutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainščak M; Jankowska E; Mueller C; Cosentino F; Lund LH; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC
Eur J Heart Fail; 2020 Nov; 22(11):1984-1986. PubMed ID: 33068051
[TBL] [Abstract][Full Text] [Related]
28. Kidney and heart failure outcomes associated with SGLT2 inhibitor use.
van der Aart-van der Beek AB; de Boer RA; Heerspink HJL
Nat Rev Nephrol; 2022 May; 18(5):294-306. PubMed ID: 35145275
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
Liu B; Wang Y; Zhang Y; Yan B
Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
[TBL] [Abstract][Full Text] [Related]
30. Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism.
Imran H; Nester W; Elgendy IY; Saad M
Ann Med; 2020 Aug; 52(5):178-190. PubMed ID: 32393068
[TBL] [Abstract][Full Text] [Related]
31. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis.
Usman MS; Bhatt DL; Hameed I; Anker SD; Cheng AYY; Hernandez AF; Jones WS; Khan MS; Petrie MC; Udell JA; Friede T; Butler J
Lancet Diabetes Endocrinol; 2024 Jul; 12(7):447-461. PubMed ID: 38768620
[TBL] [Abstract][Full Text] [Related]
32. Sodium-glucose cotransporter 2 inhibitors and cardiovascular clinical outcomes in acute heart failure: A narrative review.
Rodriguez R; Kaluzna SD
Am J Health Syst Pharm; 2023 Jun; 80(13):818-826. PubMed ID: 36971375
[TBL] [Abstract][Full Text] [Related]
33. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
Packer M
Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
[TBL] [Abstract][Full Text] [Related]
34. Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors.
Prandi FR; Barone L; Lecis D; Belli M; Sergi D; Milite M; Lerakis S; Romeo F; Barillà F
Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291558
[TBL] [Abstract][Full Text] [Related]
35. SGLT2 Inhibitors and Their Antiarrhythmic Properties.
Kolesnik E; Scherr D; Rohrer U; Benedikt M; Manninger M; Sourij H; von Lewinski D
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163599
[TBL] [Abstract][Full Text] [Related]
36. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.
Sano M
J Cardiol; 2018 May; 71(5):471-476. PubMed ID: 29415819
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients.
Chen X; Wang J; Lin Y; Yao K; Xie Y; Zhou T
Front Endocrinol (Lausanne); 2023; 14():1236404. PubMed ID: 38047108
[TBL] [Abstract][Full Text] [Related]
38. Performance of sodium-glucose cotransporter 2 inhibitors in cardiovascular disease.
Khater J; Malakouti S; Khoury AE; Cortese B
J Cardiovasc Med (Hagerstown); 2024 Apr; 25(4):247-258. PubMed ID: 38305141
[TBL] [Abstract][Full Text] [Related]
39. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
Lan NSR; Fegan PG; Yeap BB; Dwivedi G
ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
[TBL] [Abstract][Full Text] [Related]
40. SGLT2 Inhibitors' Cardiovascular Benefits in Individuals Without Diabetes, Heart Failure, and/or Chronic Kidney Disease: A Systematic Review.
Khiali S; Taban-Sadeghi M; Sarbakhsh P; Khezerlouy-Aghdam N; Rezagholizadeh A; Asham H; Entezari-Maleki T
J Clin Pharmacol; 2023 Dec; 63(12):1307-1323. PubMed ID: 37455561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
